We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
FDA approves first genetic test to help identify risk of developing opioid use disorder.
- Abstract
On Dec. 19, 2023, the U.S. Food and Drug Administration approved the first test that uses DNA in assessing whether certain individuals may have an elevated risk of developing opioid use disorder (OUD). As part of a clinical evaluation, the AutoGenomics, Inc. AvertD test is intended to be used prior to first exposure to oral opioid pain medications in patients being considered for a 4–30‐day prescription for the treatment of acute pain, such as in patients scheduled to undergo a planned surgical procedure.
- Subjects
SUBSTANCE abuse risk factors; NARCOTICS; IDENTIFICATION; GENETIC testing; PHARMACEUTICAL policy; NONPRESCRIPTION drugs; PATIENTS; UNITED States. Food &; Drug Administration; RISK assessment; DRUGS; ROUTINE diagnostic tests; DIAGNOSTIC errors; EARLY diagnosis
- Publication
Brown University Child & Adolescent Psychopharmacology Update, 2024, Vol 26, Issue 2, p8
- ISSN
1527-8395
- Publication type
Article
- DOI
10.1002/cpu30840